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Abstract
Background: Hepatic resection has the highest local controllability that results in long-term survival for hepatocellular
carcinoma (HCC). This study aimed to investigate the role of hepatic resection in selected patients of intermediate and
advanced stage.
Methods: Clinical, pathological, and outcome data of 542 consecutive patients were retrospectively analyzed from a
single center. The Kaplan-Meier method was used to estimate survival. Postoperative prognostic factors were evaluated
using univariate and multivariate analyses.
Results: The 1-, 3-, and 5-year overall survival rates were 89.0, 64.3, and 53.0 %, respectively. The 1-, 3-, and
5-year disease-free survival rates were 72.2, 44.5, and 34.2 %, respectively. Preoperative α-fetoprotein level
>400 ng/mL, macroscopic vascular invasion, microscopic portal vein thrombosis, multiple tumor nodules, and the
largest tumor size >5 cm were significantly correlated with overall survival. When these clinical risk factors were used
in a postoperative staging system, assigning one point for each factor, the total score was precisely predictive of
long-term survival. For patients with surgery plus adjuvant TACE (transarterial chemoembolization), the median overall
survival was 56 months (range 1–110 months) and the 5-year OS rate was 48.5 %.
Conclusions: Hepatic resection is efficient and safe for HCC patients of intermediate and advanced stage.
The adjuvant TACE should be recommended for HCC patients with poor risk factors.
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Background
Worldwide, hepatocellular carcinoma, the most common
primary cancer of the liver, ranks sixth among malignant
tumors in incidence and is the third leading cause of
cancer-related death [1]. In China, owing to the high
prevalence of hepatitis B viral infection and associated
liver cirrhosis, hepatocellular carcinoma (HCC) accounts
for more than 54 % of the world annual incidence, with
an estimated 372,079 mortalities [2, 3].
Hepatic resection is considered as the first-line thera-
peutic option for HCC among all treatments [4]. Liver
transplantation has the highest potential to cure because
of its ability to remove at once both the seeded HCC
and the damaged hepatic tissue [5, 6]. Milan criteria
(single HCC ≤5 cm or three HCC ≤3 cm each) showed a
4-year survival of 75 % [7]. The prognosis for patients
with HCC remains discouraging due to the recurrence
of HCC which is the main problem postoperatively and
the 5-year overall survival rate which is only 34 to 50 %
[8]. Many risk factors are known to be closely associated
with a poor long-term outcome of survival [9]. The
Barcelona Clinic Liver Cancer (BCLC) staging classifica-
tion is widely adopted because it is the only staging
system that links prognostic classification to treatment
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indications [10]. However, tumor size larger than 5 cm
and macroscopic vascular invasion were regarded as
contraindications for hepatic resection.
This article aims to explore the factors that indicate
prognosis of HCC patients included in selected inter-
mediate and advanced stage. The effect of adjuvant
TACE (transarterial chemoembolization) in patients with
poor risk factors was also investigated. The present study
was based on a prospective database and retrospective
analysis on the common parameters of 542 patients
from a single center.
Methods
Study population
Between January 2005 and December 2013, 549 con-
secutive HCC patients underwent radical hepatic resec-
tion at the Hepatopancreatobiliary Surgery Department I
of Peking University Cancer Hospital. The diagnoses of
HCC were all confirmed by histopathology.
Preoperative evaluation
Before surgery, several routine tests, including complete
blood count, a liver function panel (alanine aminotransfer-
ase [ALT], aspartate aminotransferase [AST], total biliru-
bin [TBIL], albumin [ALB], and so forth), a coagulation
panel (prothrombin time [PT], activated partial thrombo-
plastin time, and so forth), and alpha-fetoprotein (AFP)
were required for each patient. The patients also were
tested for hepatitis virus infection. Chest radiography was
taken to exclude pulmonary metastasis. Abdominal ultra-
sonography, computed tomography, and/or magnetic res-
onance imaging were applied to assess tumor resectability.
Definition of BCLC stage and resectable HCC
The BCLC stage is described as follows. Stage 0 in-
cludes single tumors smaller than 2 cm in diameter.
Stage A includes single tumors smaller than 5 cm in
diameter or up to three tumors all smaller than 3 cm
in diameter. Stage B includes up to three tumors (≥1
of which is >3 cm in diameter) or more than three
tumors of any size. Single tumors exceeding 5 cm in
diameter are included in this stage based on the art-
icle by Bruix and Llovet. Stage C includes macrovas-
cular invasion (major portal or hepatic veins).
Alternatively, stage C involves lymph node metastases
or distant metastases. Resectable HCC consists of
Child-Pugh stages A and B patients with any size
single resectable tumor or multifocal tumor which
was defined as two to three tumors exceeding 3 cm
in maximal diameter, in the absence of cancer-related
symptoms, main trunk of portal vein invasion, and/or
extra-hepatic spread [11].
Hepatic resection and adjuvant TACE
All patients underwent hepatic resection with curative
intent, as well as achieve R0, preserving as much normal
functional liver parenchyma (with adequate vascular in-
flow, outflow, and biliary drainage) as possible. Resection
of three or more segments was considered a major hep-
atic resection. The normal liver parenchyma remnant
volume was more than 30 %. For the liver cirrhosis pa-
tients, the remnant volume should be preserved more
than 40 % [12]. There was no patient who underwent
liver transplantation. Four to six weeks after hepatic re-
section, the patient with good general condition and
normal liver function received the first course of inter-
ventional therapy. Adjuvant TACE was defined as pa-
tients who chose TACE as adjuvant treatment after
hepatic resection 1 month and repeated every 4 weeks
for more than two consecutive courses. A combination
regimen of epirubicin, calcium folinate, oxaliplatin, and
fluorouracil would be administered. Informed consent
signed by every patient before treatment and approval of
the Institutional Ethics Committee were obtained.
Follow-up evaluation
All patients were followed up every 3 months for the
first 2 years, with a physical examination, liver function
tests, levels of AFP, chest radiography, and abdominal
ultrasonography. Every 6 months, the patients would
undergo computed tomography (CT) scan and/or MRI.
The last follow-up evaluation was censored on February
1, 2015, or up to the time of death.
Statistics
Continuous variables were summarized as a mean, and
categorical variables were summarized as frequency and
percentage. Statistical comparison between qualitative
variables was performed with the Pearson chi-square
test. Kaplan-Meier survival was calculated from the date
of hepatic resection, and significant differences were
determined with a log-rank test. Univariate and multi-
variate analyses of various clinicopathological factors by
Cox’s proportional hazard model were used to identify
independent risk factors for overall survival. The linear
regression was performed to describe the predictors of
long-term survival. All p values were based on a two-
sided test of statistical significance. Significance was
accepted at p < 0.05. Statistical analysis was performed
using SPSS 19.0 (SPSS, Inc., Chicago, IL, USA).
Results
Patients characteristic
Between January 2005 and December 2013, 549 patients
who underwent surgical resection were investigated.
Seven (1.3 %) patients were lost in the follow-up. There-
fore, 542 patients were enrolled. It included 458 male
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and 84 female patients, with a median age of 56 years
(range 27–88). The mean TBIL was 15.7 ± 6.9 μmol/L
(range 2–48, median 14.7 μmol/L). The mean ALB was
43.55 ± 4.7 g/L (range 31–56, median 43.75 g/L). The
mean PT was 12.5 ± 1.46 s (range 9–17, median 12 s). The
mean preoperative AFP level was 227.12 ± 118.21 ng/mL
(range 1–1018, median 118 ng/mL) (Table 1).
Surgery details and early postoperative outcome
A major hepatic resection was performed in 144 (26.57 %)
patients. According to the Clavien-Dino classification
system, 86 patients underwent minor complications
(Clavien grade <3) (Table 1). There were 17 patients
with PT >14 s. No liver failure happened to them.
Only one of them suffered from transient diarrhea
after hepatic resection.
Pathological results and prognostic factors for overall
survival
The mean tumor size was 5.27 ± 3.28 cm (range 0.5–19,
median 4.5 cm). Multiple tumor nodules but ≤3 was
detected in 66 (12.18 %) patients. Microscopic portal vein
thrombosis was detected in 143 (26.38 %) patients. Macro-
scopic vascular invasion was detected in 54 (9.96 %)
patients (Table 1). Overall survival was influenced by
preoperative AST level (p = 0.001), AFP level (p = 0.009),
the largest tumor size (p < 0.001), multiple tumor nodules
(p < 0.001), microscopic portal vein thrombosis (p <
0.001), macroscopic vascular invasion (p < 0.001), blood
lose (p = 0.042), blood transfusion (p < 0.001), and type
of hepatic resection (p < 0.001) in univariate analysis.
Multivariate analysis showed that preoperative AFP (p =
0.010), the largest tumor size >5 cm (p < 0.001), multiple
tumor nodules (≤3) (p < 0.001), microscopic portal vein
Table 1 Patients and tumor characteristics
Variable No. of patients
Patients demographics
Gender (male/female) 458 (84.5 %)/84 (15.5 %)
ECOG (0/1/2) 312 (57.6 %)/170 (31.4 %)/60 (11 %)
Age (year) (≤60 vs. >60 years) 361 (66.6 %)/181 (33.4 %)
Hepatitis B (+/−) 421 (77.7 %)/118 (22.3 %)
Hepatitis C (+/−) 39 (7.2 %)/503 (92.8 %)
AFP level (≤400 vs. >400 ng/mL) 414 (76.4 %)/128 (23.6 %)
ALT level (≤40 vs. >40 U/L) 350 (64.6 %)/192 (35.4 %)
AST level (≤40 vs. >40 U/L) 331 (61.1 %)/211 (38.9 %)
TBIL level (≤17.5 vs. >17.5 μmol/L) 356 (65.7 %)/186 (34.3 %)
ALB level (≤35 vs. >35 g/L) 22 (4.1 %)/520 (95.9 %)
PT (≤14 vs. >14 s) 525 (96.9 %)/17 (3.1 %)
Liver cirrhosis (+) 390 (72.0 %)/150 (28.0 %)
Tumor characteristics
Tumor size (≤5 vs. >5) 325 (60.0 %)/217 (40.0 %)
No. of tumor (single vs. multiple) 473 (87.3 %)/69 (12.7 %)
Microscopic portal vein thrombosis (+/−) 143 (26.4 %)/399 (73.6 %)
Macroscopic vascular invasion (+/−) 54 (10.0 %)/488
Surgery details
Operation time (min) 148 ± 55.6
Blood lose (≤1000 vs. >1000 mL) 506 (93.4 %)/36 (6.6 %)
Blood transfusion (n) 60 (11.1 %)
Type of liver resection (minor vs. major) 398 (73.4 %)/144 (26.6 %)
Complications
Minor (Clavien grade <3) 86 (15.9 %)
Major (Clavien grade ≥3) 23 (4.2 %)
Hospital stay (day) 13.8 ± 11.6
Child-Pugh grade (A/B) 538 (99.3 %)/4 (0.7 %)
BCLC stage (0/A/B/C) 76 (14.0 %)/208 (38.4 %)/204 (37.6 %)/54 (10 %)
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thrombosis (p = 0.014), and macroscopic vascular invasion
(p = 0.017) were the independent prognostic factors for
poor OS (Table 2).
Survival analysis
The median follow-up was 69 months (range 1–
111 months). Seven (1.29 %) patients were lost in the
follow-up. Cancer in 305 (56.27 %) patients recurred
after surgery, and 206 (38.01 %) of them died of cancer
recurrence. The 1-, 3-, and 5-year disease-free survival
(DFS) rates were 72.2, 44.5, and 34.2 %, respectively The
1-, 3-, and 5-year overall survival (OS) rates were 89.0,
64.3, and 53.0 %, respectively (Fig. 1). According to the
BCLC staging system, the 5-year OS rate for BCLC
stages 0, A, B, and C was 72.4, 66.3, 36.9, and 28.9 %,
respectively (p < 0.001) (Fig. 2). The five clinical risk
factors that are preoperative AFP level >400 ng/mL, the
largest tumor size > 5 cm, multiple tumor nodules,
macroscopic vascular invasion, and microscopic portal
vein thrombosis were chosen. The more risk factors
Table 2 Prognostic factors of overall survival and disease-free survival
OS DFS
Analysis OR 95 % CI p value OR 95 % CI p value
Univariate
Male sex 1.092 0.741–1.609 0.653 0.975 0.716–1.328 0.873
Age >60 years 0.848 0.633–1.135 0.263 0.934 0.737–1.185 0.572
ECOG (0/1/2) 0.681 0.426–1.112 0.752 0.704 0.421–1.191 0.726
Child-Pugh A/B 3.123 0.995–9.800 0.099 1.780 0.570–5.560 0.364
HBV (+) 1.050 0.754–1.463 0.772 1.140 0.863–1.505 0.350
HCV (+) 1.142 0.695–1.876 0.608 1.174 0.773–1.782 0.462
AST >40 U/L 1.592 1.209–2.096 0.001 1.528 1.217–1.919 <0.001
ALT >40 U/L 1.142 0.866–1.506 0.348 1.192 0.949–1.496 0.133
TBIL >17.5 μmol/L 0.789 0.584–1.066 0.117 0.854 0.671–1.086 0.194
ALB ≤35 g/L 1.154 0.628–2.119 0.651 1.422 0.859–2.353 0.239
PT >14 s 2.012 1.064–3.803 0.052 2.191 0.780–3.753 0.401
AFP >400 ng/mL 1.516 1.118–2.057 0.009 1.434 1.113–1.847 0.007
Liver cirrhosis (+) 0.890 0.658–1.204 0.450 1.030 0.798–1.329 0.821
Tumor size >5 cm 2.925 2.212–3.867 <0.001 1.904 1.518–2.388 <0.001
Microscopic portal vein (+) 2.281 1.714–3.035 <0.001 1.825 1.432–2.325 <0.001
Macroscopic vascular invasion (+) 2.819 1.963–4.048 <0.001 2.228 1.616–3.082 <0.001
Multiple nodes but ≤3 2.818 1.975–4.058 <0.001 2.486 1.823–3.390 <0.001
Blood loss >1000 mL 1.649 1.049–2.591 0.042 1.032 0.618–1.641 0.327
Blood transfusion (+) 3.310 2.402–4.561 <0.001 1.229 0.712–1.548 0.614
Complications (+) 1.254 0.937–1.679 0.133 1.439 1.130–1.832 0.003
Major liver resection 2.475 1.854–3.258 <0.001 1.941 1.528–2.465 <0.001
Adjuvant TAC/TACE 1.132 0.683–2.126 0.627 0.134 0.512–1.168 0.079
Multivariate
AST >40 U/L 1.044 0.722–1.510 0.818 0.860 0.611–1.209 0.385
AFP >400 ng/mL 1.523 1.107–2.095 0.010 1.213 0.922–1.598 0.168
Tumor size >5 cm 2.002 1.443–2.778 <0.001 1.489 1.129–2.078 0.013
Microscopic portal vein (+) 1.559 1.126–2.159 0.007 1.266 0.967–1.657 0.086
Macroscopic vascular invasion (+) 1.655 1.096–2.499 0.017 0.982 0.672–1.435 0.926
Multiple nodes but ≤3 2.134 1.460–3.120 <0.001 0.888 0.636–1.239 0.484
Blood loss >1000 mL 1.142 0.708–1.842 0.585 1.073 0.696–1.654 0.749
Blood transfusion 1.025 0.686–1.531 0.904 1.238 0.945–1.621 0.121
Major liver resection 1.348 0.964–1.887 0.081 1.100 0.836–1.449 0.495
Complications 1.136 0.877–1.472 0.333
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accumulated, the poorer the prognosis of the patient is.
The 5-year overall survival rate of risk factors 0, 1, 2, 3
and 4 was 72.9, 60.8, 30.8, 11.7, and 8.6 %, respectively
(Additional file 1: Figure S1).
Adjuvant TACE for patients with risk factors
Among the patients with clinical risk factors that are in-
dependent prognostic factors for poor OS in multivariate
analysis, 162 underwent adjuvant TACE. There was no
significant difference in clinical characteristics of pa-
tients. Patients in adjuvant TACE group had smooth re-
covery after treatment. No serious complication or
hospital death occurred (Additional file 2: Table S1). For
patients with surgery plus adjuvant TACE, the median
DFS was 23 months (range 1–110 months), and the 5-
year DFS rate was 33.0 % (n = 162). It differs significantly
from the patients with surgery alone (n = 205). The me-
dian DFS was 21 months (range 1–75 months), and the
5-year DFS rate was 21.6 % (p = 0.033) (Additional file 3:
Figure S2A). For patients with surgery plus adjuvant
TACE, the median OS was 56 months (range 1–
110 months) and the 5-year OS rate was 48.5 %. It dif-
fers significantly from the patients with surgery alone.
The median OS was 35 months (range 1–88 months),
and the 5-year OS rate was 38.7 %(p = 0.016) (Additional
file 3: Figure S2B).
Literature review
A total of 24 eligible studies were found to satisfy the in-
clusion criteria, and the key demographic and clinico-
pathological data were extracted (Table 3). Studies were
organized into subgroups depending on whether they in-
volved large and/or multinodular HCC [13–29] (BCLC
stage B) and HCC with macrovascular invasion [30–36]
(BCLC stage C). The majority of the studies reported
hospital mortality less than 11.1 %. The overall survival
after hepatic resection were 45 to 99 % (1 year), 17 to
84.2 % (3 years), and 10 % to 65 % (5 years).
Discussion
The present study containing 542 consecutive patients
represents an institutional review of surgical resection as
the initial primary therapy for HCC from tertiary referral
hospital. In the present study, factors that resulted in
poor long-term outcomes after hepatic resection were
identified, including preoperative AFP level, macroscopic
vascular invasion, the largest tumor size >5 cm, multiple
tumor nodules, and microscopic portal vein. These fac-
tors objectively predict the long-term outcome of the re-
sectable HCC: the more risk factors accumulated, the
poorer the prognosis is.
More than 70 % of HCC patients have AFP secretion,
and a high serum level of AFP (>400 ng/mL) may be an
indirect measure of tumor burden [37]. The prognostic
significance of AFP also has been testified in multiple
studies [38]. Multiple tumor nodules were considered to
be a poor factor of survival [39]. Multifocal hepatocellu-
lar carcinoma (HCC) may be multiple HCCs of multi-
centric origin (MO) or intrahepatic metastases (IM)
arising from a primary HCC. Numerous attempts to dif-
ferentiate the two types of multifocal HCC have been
made due to the different prognosis of two types [40].
Tumor larger than 5 cm was an important indicator of a
high risk of recurrence, a higher incidence of intrahepa-
tic metastasis and portal venous invasion [41]. It was
classified into BCLC B stage, which correlated with a
high risk of intraoperative blood loss and postoperative
liver failure, leading them to be against HR for HCC
outside the Milan criteria [42]. Macroscopic vascular in-
vasion was classified into stage C that sorafenib was
recommended as treatment [42]. Therefore, hepatic re-
section is not recommended as the first-line treatment
Fig. 1 Kaplan-Meier curve showing OS and DFS for 542 HCC patients
Fig. 2 Kaplan-Meier curve showing OS according to BCLC stage for
542 HCC patients
Liu et al. World Journal of Surgical Oncology  (2016) 14:62 Page 5 of 8
for single large, multinodular, and macrovascular inva-
sion HCCs according to the BCLC stage system.
However, the BCLC staging classification was based on
a 15-year-old study and drew its conclusion from the
prognostic analysis of HCC patients who were predomin-
antly HCV infected and received curative treatment. This
staging may not reflect cancer progression or prognosis in
HCC patients for whom HBV infection is the predomin-
ant etiological factor [42]. HBV-associated HCC generally
exhibit a better preserved liver function than HCV-
associated patients. As a result of recent advances in surgi-
cal techniques and preoperative management, the indica-
tions for hepatic resection have expanded, and hepatic
resection has become a reasonably safe treatment option
with an acceptable mortality rate [43]. Studies have testi-
fied that if patients had preserved liver function, hepatic
resection still achieved better survival results than other
treatments for BCLC B stage [15, 44]. Actually, the inter-
mediate and advanced stage of HCC comprises a highly
heterogeneous population, in that patients may differ ac-
cording to tumor load, age, liver function, and possible co-
morbidities, which fall under BCLC stages B and C and
can vary greatly. According to this study, the extension of
hepatic resection was related to blood loss in operation
and morbidity of biliary fistula, which increased the length
of hospital stay but the complication was not independ-
ently correlated to the survival of HCC. Nevertheless,
studies from both the West and the East clearly have
shown that surgical resection could be performed safely
and led to long-term survival in these subsets of HCC
patients [32, 33]. In the present study, the 5-year OS rate
for BCLC stages 0, A, B and C was 72.4, 66.3, 36.9, and
28.9 %, respectively (p < 0.001), which is in accordance
with previous reports.
The main effects of postoperative TACE on HCC are
the following: to inhibit remnant tumor growth, detect it
early, and to treat tiny metastases [45]. The concentra-
tion of chemotherapeutics within tumor tissue can be
Table 3 Outcomes of hepatic resection for patients with BCLC stage B/C HCC in literature review











1 year 3 years 5 years
Single, large, and/or multinodular HCC
Cheng et al. [13] Taiwan 1999–2005 104 >5 cm 7.3 – 90 – 66
Heng-Jun et al. [14] China 2000–2009 151 BCLC B – 61.8 99 68 52
Ho et al. [15] Taiwan 1981–2000 294 BCLC B – 37.9 77.4 51.9 36.6
Hsu et al. [16] Taiwan 2002–2010 268 BCLC B+C 2.7 – 81 63 43
Jin et al. [17] South Korea 1998–2013 62 BCLC B 11.1 – 83.2 75.7 65
Jianyong et al. [18] China 2002–2008 433 BCLC B 2.3 – 91.8 84.2 70.8
Lee et al. [19] Korea 1997–2003 100 >10 cm 2.0 – 66 44 31
Lim et al. [20] Japan 1994–2010 172 >5 cm 1 – – – 58
Lin et al. [21] Taiwan 2001–2007 93 BCLC B 5.4 29.9 ± 20.1 83 49 –
Ng et al. [22] Asia, Europe, USA 1982–2001 380 >5 cm 2.7 – 74 50 39
Nojiri et al. [23] Japan 1992–2011 107 >5 cm – – – 62 38.1
Pandey et al. [24] Singapore 1995–2006 166 >10 cm 3.0 – – – 29
Poon et al. [25] Hong Kong 1991–2000 120 >10 cm 5.0 – 61 38 28
Wang et al. [26] Taiwan 1986–2002 243 BCLC B – 60.4 ± 6.1 81.5 64.4 50.5
Yin et al. [27] China 2008–2010 88 BCLC B 11.3 41 76.1 51.5 –
Zhong et al. [28] China 2000–2010 660 BCLC B 2.6 – 91 67 44
Zhong et al. [29] China 2000–2007 257 BCLC B 3.1 42.9 ± 26.1 84 59 37
Macrovascular invasion HCC
Chang et al. [30] Taiwan 1991–2006 160 BCLC C 2.7 – 58 34 29
Huang et al. [31] China 1998–2008 116 >15 cm 3.4 – 71 23 11
Ikai et al. [32] Japan 1992–2003 976 BCLC C 2.5 – 50 26 18
Pawlik et al. [33] Asia, Europe, USA 1984–1999 102 BCLC C 5.9 – 45 17 10
Shi et al. [34] China 2001–2003 406 BCLC C 0.2 – 34 13 –
Torzilli et al. [35] China, Europe, USA 1990–2009 297 BCLC C 3.0 – 76 49 38
Yang et al. [36] China 2001–2007 511 BCLC C 3.0 – 70 41 31
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achieved 10–100 times higher than systemic therapy [46]. It
was usually believed that multi-intrahepatic tumor and
portal vein tumor thrombosis could not be totally removed.
The patient with such risk factors is recommended to
receive TACE 1–2 months after resection [47].
Treatment decision of HCC should be based on a
multidisciplinary interaction between different specialists
[6]. This approach necessitates the involvement of mul-
tiple specialists to provide individualized treatment
strategies. Guidelines, although useful, must be adapted
to the advances of HCC [48]. BCLC B and C HCC might
benefit from perioperative treatment including the con-
trol of portal hypertension, reduction of tumor burden,
and virosuppression of hepatitis [49]. Combined to these
multiple individualized treatment strategies, in most
Asian centers owing to higher case volume and expert-
ise, it was well recognized that a more aggressive treat-
ment approach has been adopted [50].
Limitation
There were several limitations of this study. First, the
present study was retrospective in nature and without
control group. It thus was subject to potential bias that
might prevent definite conclusions to be drawn. Second,
it will be of interest to evaluate how our staging system
compares with the BCLC staging in a Western HCC pa-
tient population because the more aggressive treatment
guidelines may yield a better survival outcome in non-
Asian HCC patients as well. Third, hepatic resection was
performed only on patients with no more than three
nodules. For four or more tumors, TACE or other pallia-
tive care was recommended [11]. Therefore, the patients
enrolled in present study were limited to patients with
no more than three nodules. Finally, there is no further
validation which should be performed in the future.
Conclusions
Hepatic resection is efficient and safe for HCC patients
of intermediate and advanced stage. The adjuvant TACE
should be recommended for HCC patients with poor
risk factors.
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